Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Heterogeneity in advanced pulmonary sarcomatoid carcinoma and its efficacy to immune checkpoint inhibitors.

European journal of cancer (Oxford, England : 1990) - 1 Sept 2024

Xie Mengqing, Chu Tianqing, Dong Xiaorong, Wang Huijuan, Chu Qian, Cai Xiuyu, Wang Jialei, Yao Yu, Wu Lin, Ye Feng, Zhu Bo, Zhou Caicun, Su Chunxia

Abstract excerpt

BACKGROUND: Immune checkpoint inhibitors (ICIs) have improved the prognosis of patients with non-small cell lung cancer but rarely been explored in pulmonary sarcomatoid carcinoma (PSC). This multicenter study aimed to evaluate the effectiveness of ICIs for PSC and its underlying mechanism. METHODS: Advanced PSC who received ICIs between August 2018 and May 2022 from 11 centers in China were included. Clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Angiogenesis Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Exome Sequencing

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Mutation

Share to Prognosis

Source

Identifiers

PMID: 39111208
DOI: 10.1016/j.ejca.2024.114260

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Heterogeneity in advanced pulmonary sarcomatoid carcinoma and its efficacy to immune checkpoint inhibitors.PMID 39111208Read ↗

Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53.Semantic proximity Read ↗

Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomesSemantic proximity Read ↗

Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma.Semantic proximity Read ↗

Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma.Semantic proximity Read ↗

Integrated Clinical, Molecular and Immunological Characterization of Pulmonary Sarcomatoid Carcinomas Reveals an Immune Escape Mechanism That May Influence Therapeutic Strategies.Semantic proximity Read ↗

Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and TP53 mutant undifferentiated lung cancer.Semantic proximity Read ↗

The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients.Semantic proximity Read ↗

Analysis of molecular pathologic and clinical features of 36 patients with pulmonary sarcomatoid carcinomaSemantic proximity Read ↗

Mutational Landscape and Treatment Response in Extensive-Stage Small-Cell Lung Cancer: A Single-Center Real-World Analysis.Semantic proximity Read ↗

Effective treatment strategies and key factors influencing therapeutic efficacy in advanced SMARCA4-deficient non-small cell lung cancer.Semantic proximity Read ↗

Analysis of molecular pathologic and clinical features of 36 patients with pulmonary sarcomatoid carcinoma.Semantic proximity Read ↗

New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profilesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.